PR/PGR (phospho-S294) polyclonal antibody

Product Specifications

Background

The effects of progesterone are mediated by two functionally different isoforms of the progesterone receptor, PR-A and PR-B, which are transcribed from distinct, estrogen inducible promoters within a single copy of the PR gene. The PR-A and PR-B proteins are 90 kDa and 118 kDa respectively; the first 164 amino acids of PR-B are absent in PR-A. Progesterone bound PR-A and PR-B have different transcription activation properties. Specifically, PR-B functions as a transcriptional activator in most cell and promoter contexts, while PR-A is transcriptionally inactive and functions as a strong ligand dependent transdominant repressor of steroid hormone receptor transcriptiona activity. An inhibitory domain (ID), which maps to the amino terminus of the receptor, exists within both PR isoforms.

CAS Number

9007-83-4

Structure Composition

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Product Name Alternative

NR3C3; PGR; PRGR; Progesterone receptor

Swiss Prot

P06401

Reactivity

Human, Mouse, Rat

Immunogen

Synthetic phosphopeptide derived from human PGR around the phosphorylation site of Serine 294.

Conjugation

Unconjugated

Related Pathways

Nuclear Receptor Signaling

Applications

Dilution

WB: 1:500~1:1000

Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Modification

Phosphorylation

Molecular Weight

~ 90 kDa (PR-A) ~ 118 kDa (PR-B)

Storage Conditions

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Notes

For research use only, not for use in diagnostic procedure.

Specificity

P-PR/PGR (S190) polyclonal antibody detects endogenous levels of Progesterone Receptor protein only when phosphorylated at Ser190.

Applications Notes

Western blot (WB) analysis of p-PGR (S294) polyclonal antibody at 1:500 dilution Lane1:HEK293T cell lysate treated with EGF (0.1ng/ML,30mins) Lane2:sp2/0 cell lysate treated with EGF (0.1ng/ML,15mins) Lane3:PC12 cell lysate treated with PMA (100nM,15mins)